Sandhya Sapra, Lung Tumor Lead at AstraZeneca, shared on LinkedIn:
“I am pleased to share that I’ve joined AstraZeneca as the Lung Tumor Lead for Oncology Outcomes Research (O2R).
Still learning the acronyms. Apparently, 15+ years in the industry doesn’t get you an exemption.
What has stood out to me is the quality of both the science and the people. I’ve appreciated the open conversations, the willingness to hear different perspectives, and the warmth of colleagues who have made me feel welcome from the start. It’s been a refreshing reminder of how much the environment we work in matters.
I’m looking forward to working with my team to build evidence that helps us better understand and improve outcomes for people living with lung cancer. It’s work I care deeply about, and I am grateful for the opportunity to contribute.
Thank you to my colleagues for such a thoughtful welcome. I’m very happy to be here.”
You may also be interested in:
- AstraZeneca and Tempus AI Renew $200M Oncology Deal
- Jamie John։ Keeping Patient Voices at the Center of Lung Cancer Awareness
